Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Cephalothin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 469 records · Page 26Linked to original sources
PubMed1979

In vitro activity of piperacillin compared with that of carbenicillin, ticarcillin, ampicillin, cephalothin, and cefamandole against Pseudomonas aeruginosa and Enterobacteriaceae.

Piperacillin (T-1220), a semisynthetic derivative of aminobenzylpenicillin, was more active than either carbenicillin or ticarcillin against Pseudomonas aeruginosa; over 60% of isolates were inhibited at a concentration of 6.3 mug/ml. Piperacillin was bactericidal for 84% of Pseudomonas strains at 100 mug/ml, carbenicillin killed 60%, and ticarcillin killed 68% at that concentration. Piperacillin was also more active than the other penicillins against isolates of Escherichia coli, Enterobacter, and Proteus mirabilis. The combination of piperacillin and tobramycin, demonstrating synergistic inhibition of 87% of strains of P. aeruginosa, was the most active of the penicillin-aminoglycoside combinations tested for synergism.

Ampicillin↗
PubMed1981

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.

Thirty patients infected predominantly by Serratia marcescens and Pseudomonas aeruginosa were treated in an open trial with moxalactam, a broad-spectrum beta-lactam antibiotic. Twenty-three (76%) had a satisfactory microbiological or clinical response. Among 25 patients for whom serum inhibitory concentrations were measured, those with favorable microbiological responses had significantly higher values than those with poor responses (reciprocal geometric mean concentrations, 49 versus 4.9; P less than 0.01). A serum inhibitory concentration of greater than 1:8 correlated significantly with a favorable outcome (17 of 18 versus 2 of 7 responses; P less than 0.01). Although the overall clinical efficacy of moxalactam was good, resistant organisms of species identical to those of the original infecting isolates were recovered during therapy in seven cases, including five caused by Pseudomonas organisms and two caused by Serratia organisms.

Adult↗